share_log

Morgan Stanley Maintains Equal-Weight on Lyell Immunopharma, Lowers Price Target to $4

Benzinga Real-time News ·  Jan 24, 2023 09:04

Morgan Stanley analyst Matthew Harrison maintains Lyell Immunopharma (NASDAQ:LYEL) with a Equal-Weight and lowers the price target from $7 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment